The "hidden" epidemic: A snapshot of Moroccan intravenous drug users

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Trimbitas, Roxana Delia ^a   Serghini, Fatima Zahra ^b   Lazaar, Fatiha ^a   Baha, Warda ^a   Foullous, Abderrahim ^a   Essalhi, Mohammed ^b   El Malki, Abdelouahed ^a   Meziane Bellefquih, Abdelkrim ^c   Bennani, Abdelouaheb ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b Hasnouna Center of Addictology   (Morocco)

^c Ministry of Health Morocco   (Morocco)

Author keywords

Genotype; Hepatitis C; IDUs; Morocco; Prevalence; Public health; Risk factors

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; EPIDEMIC; FEMALE; FRANCE; GENOTYPE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MOROCCO; RISK FACTOR; SAMPLE SIZE; SEROPREVALENCE; SPAIN; VIRUS TRANSMISSION;

HEPATITIS C VIRUS;

ADULT; DRUG USERS; EPIDEMICS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOROCCO; RETROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84899552765     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-43     Document Type: Article

References (55)

1. High incidence of Hepatitis C virus reinfection in a cohort of injecting drug users. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hellard M, Hepatology 2008 48 6 1746 1752 10.1002/hep.22534 18844233
2. The scientific challenge of Hepatitis C. Cohen J, Science 1999 285 5424 26 30 10.1126/science.285.5424.26 10428695
3. Hepatitis C viral clearance, reinfection, and persistence, with insights from studies of injection drug users: towards a vaccine. Grebley J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR, Dore GJ, The Lancet 2012 12 408 414
4. Targeted drugs to tackle hepatitis C. Mole B, Nature 2013 497 7447 18 19 10.1038/497018a 23636373
5. Current progress in development of Hepatitis C vaccines. Liang TJ, Nat Med 2013 19 869 878 10.1038/nm.3183 23836237
6. Hepatitis C virus in the Arab world: a state of concern. Daw M, Dau A, The Scientific World Journal 2012 2012 719494
7. The Epidemiology of Hepatitis C virus in Egypt: a systemic review and data synthesis. Mohamoud Y, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ, BMC Infect Dis 2013 133 288
8. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Miller FD, Laith AR, Proc Natl Acad Sci U S A 2010 107 33 14757 14762 10.1073/pnas.1008877107 20696911
9. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. Baha W, Foullous A, Dersi N, They-they TP, El alaoui K, Nourichafi N, Oukkache B, Lazar F, Benjelloun S, Ennaji MM, Elmalki A, Mifdal H, Bennani A, BMC Public Health 2013 13 50 10.1186/1471-2458-13-50 23331910
10. Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction. Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M, Pathologie Biologie 2009 57 368 372 10.1016/j.patbio.2008.07.006 18842351
11. Epidemiologic and virologic study of hepatitis C virus infections in Morocco. Cacoub P, Ohayon V, Sekkat S, Dumont B, Sbai A, Lunel F, Benslimane A, Godeau P, Archane MI, Gastroenterologie Clinique et Biologie 2000 24 2 169 173
12. Hepatitis C virus infection and injection in intravenous drug user: prevention, risk factors, and treatment. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R, Clin Infect Dis 2005 15 40 Suppl 5 330 335
13. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Miller M, Haley C, Koziel MJ, Rowley CF, Clin Infect Dis 2005 41 5 713 720 16080095
14. Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population. Ramia S, Melhem M, Kreidieh K, Infection 2012 40 1 10
15. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S, Virol J 2010 7 96 10.1186/1743-422X-7-96 20465784
16. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Raptopoulou M, Touloumi G, Tzourmakliotis D, Nikolopoulou G, Dimopoulou M, Giannoulis G, Vasiliadis T, Skoutelis A, Anagnostou O, Hatzis G, Manolakopoulos S, Hippokratia 2011 15 1 26 31 21607032
17. HCV Genotypes in patients with chronic hepatitis C in Croatia. Vince A, Palmović D, Kutela N, Sonicky Z, Jeren T, Radovani M, Infection 1998 26 3 173 177 10.1007/BF02771846 9646111
18. Distribution of HCV genotypes among risk groups in Serbia. Stamenkovic G, Zerjav S, Velickovic ZM, Krtolica K, Samardzija VL, Jemuovic L, Nozic D, Dimitrijevic B, Eur J Epidemiol 2001 16 949 954
19. Prevalence of hepatitis C virus genotypes in southern Italy. Cicciarello S, Borgia G, Crowell J, Ciampi R, Cerini R, Orlando R, Mainolfi M, Reynaud L, Milano M, Piazza M, Eur J Epidemiol 1997 13 1 49 54 10.1023/A:1007324300358 9062779
20. Hepatitis C virus among intravenous drug users in Italy. Stroffolini T, Fiumeb A, Fataleb G, Regnib F, Ciccozzia M, Marzolinia A, Mele A, Hepatology Research 1997 9 20 27 10.1016/S1386-6346(97)00084-3
21. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, et al. J Viral Hepat 2005 12 405 413 10.1111/j.1365-2893.2005.00605.x 15985012
22. Relation of hepatitis C virus genotypes to risk factors and hepatic disease in Spanish patients. Alonso Alonso AP, Orduña A, San Miguel A, Dominguez E, Bratos MA, Gutierrez MP, Eiros JM, Inglada L, Gonzalez Hernandez JM, Rodriguez Torres A, Clin Microbiol Infect 1997 3 36 647 652 11864207
23. Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. Almeida Calado R, Rocha MR, Parreira R, Piedade J, Venenno T, Esteves A, J Med Virol 2011 83 608 615 10.1002/jmv.21955 21328374
24. Prevalence of anti-HCV antibodies and seroconversion incidence in five haemodialysis units in Morocco. Sekkat S, Kamal N, Benali B, Fellah H, Amazian K, Bourquia A, El Kholti A, Benslimane A, Nephrol Ther 2008 4 105 110 18272446
25. HCV genotypes in Morocco. Benani A, El-Turk J, Benjelloun S, Sekkat S, Nadifi S, Hda N, Benslimane A, J Med Virol 1997 52 4 396 398 10.1002/(SICI)1096-9071(199708)52:4<396::AID-JMV9>3.0.CO;2-X 9260687
26. Anti-HCV seroprevalence and risk factors of hepatitis C virus infection in Moroccan population groups. Benjelloun S, Bahbouhi B, Sekkat S, Bennani A, Hda N, Benslimane A, Res Virol 1996 147 4 247 255 10.1016/0923-2516(96)89656-7 8837233
27. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, Zouridakis K, Bellou AL, Orfanou E, Raptopoulou-Gigi M, Addict Med 2013 7 1 52 57 10.1097/ADM.0b013e318279756f
28. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin BR, Marincola FM, O'Brien TR, Hepatology 2012 56 1 86 94 10.1002/hep.25652 22331649
29. Systematic review of HIV and HCV infection among drug users in China. Bao YP, Liu ZM, International Journal of STDs & AIDS 2009 20 399 405 10.1258/ijsa.2008.008362
30. Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? Mathei C, Butinax F, Van Damme P, J Infect Dis 2001 184 659 660 10.1086/322795 11494175
31. Comparison of hepatitis C virus treatment between incarcerated and community patients. Rice J, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, Sawyer J, Striker R, Lucey MR, Hepatology 2012 56 4 1252 1260 10.1002/hep.25770 22505121
32. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N, Wilhelm C, Steinmann J, Pietschmann T, Steinmann E, J Infect Dis 2013 207 81 87
33. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Amjad A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA, Virol J 2011 8 466 10.1186/1743-422X-8-466 21982599
34. Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey. Yildiz E, Oztan A, Sar F, Pinarbasi E, Cetin-Atalay R, Akkiz H, Ozturk M, Virus Genes 2002 25 2 169 177 10.1023/A:1020161818764 12416679
35. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. Lopez-Labrador F, Ampurdanés S, Forns X, Castells A, Sáiz JC, Costa J, Bruix J, Sánchez Tapias JM, de Anta MT J, Rodés J, J Hepatol 1997 27 959 965 10.1016/S0168-8278(97)80137-7 9453419
36. Association of hepatitis C virus infection and diabetes. Rouabhia S, Malek R, Bounecer H, World J Gastroenterol 2009 15 40 5114 5115 10.3748/wjg.15.5114 19860010
37. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). Xu LZ, Larzul D, Delaporte E, Brechot C, Kremsdorf D, J Gen Virol 1994 75 2393 239 10.1099/0022-1317-75-9-2393 8077938
38. Evolvingepidemiology of hepatitis C virus. Lavanchy D, Clin Microbiol Infect 2011 17 107 115 10.1111/j.1469-0691.2010.03432.x 21091831
39. Subtype distribution among intravenous drug users with chronic type C hepatitis in southern Spain. Garcia F, Roldán C, García F Jr, Hernández J, García-Valdecasas J, Bernal MC, Piédrola G, Maroto MC, Microbios 1998 95 380 15 24 9881460
40. Comparison of Hepatitis C virus viral loads in patients with or without coinfection with different genotypes. Schijman A, Colina R, Mukomolov S, Kalinina O, García L, Broor S, Bhupatiraju AV, Karayiannis P, Khan B, Mogdasy C, Cristina J, Clin Diagn Lab Immunol 2004 11 2 433 435 15014001
41. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Matthews-Greer J, Caldito G, Adley S, Willis R, Mire A, Jamison R, McRae K, King J, Chang WL, Clin Vaccine Immunol 2001 8 4 690 694 10.1128/CDLI.8.4.690-694.2001
42. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F, AIDS 1995 9 10 1131 1136 10.1097/00002030-199510000-00003 8519448
43. HCV therapy in HIV-infected patients. Sulkowsky M, Liver Int 2013 33 Suppl 1 63 70 23286848
44. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. Filippini P, Coppola N, Pisapia R, Martini S, Marrocco C, Di Martino F, Sagnelli C, Filippini A, Sagnelli E, J Med Virol 2007 79 1679 1685 10.1002/jmv.20992 17854026
45. How to optimize HCV therapy in genotype 1 patients: predictors of response. Petta S, Craxi A, Liver Int 2013 33 Suppl 1 23 29 23286842
46. How to optimize HCV therapy in genotype 2 patients. Grassi E, Aghemo A, Liver Int 2013 33 Suppl 1 35 40 23286844
47. The future for the treatment of genotype 4 chronic hepatitis C. Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME, Liver Int 2012 32 Suppl 1 146 50 22212586
48. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Chopra A, Klein PL, Drinnan T, Lee SS, Liver Int 2013 33 Suppl. 1 30 40 23286843
49. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. Pellicelli A, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D'Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G, BMC Gastroenterol 2012 12 162 10.1186/1471-230X-12-162 23157720
50. Clinical significance of Hepatitis C virus genotypes. Zein N, Clin Microbiol Rev 2000 13 2 223 235 10.1128/CMR.13.2.223-235.2000 10755999
51. Direct-Acting Antiviral Medications for Chronic Hepatitis C Virus Infection. Jazwinski A, Muir A, Gastroenterology & Hepatology 2011 7 30 154 162 21528041
52. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Andriulli A, Dalgard O, Bjoro K, Mangia A, Dig Liver Dis 2006 38 10 741 748 10.1016/j.dld.2006.06.006 16916631
53. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J, J Hepatol 2004 40 993 999 10.1016/j.jhep.2004.02. 007 15158341
54. Limited Uptake of Hepatitis C Treatment among Injection Drug Users. Mehta S, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL, J Community Health 2008 33 3 126 133 10.1007/s10900-007-9083-3 18165889
55. Best strategies for global HCV eradication. Hegan LM, Schinazi RF, Liver Int 2012 54 68 79